About NexgenRx (CVE:NXG)
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans in Canada. It offers prescription drug claims; dental claims; and claims for extended health benefits, as well as provides a health care spending account that offers an amount of money to an individual to pay for health or dental benefits. The company also provides individual and aggregate stop loss products; medical emergency and travel assistance insurance services; administrative services, including the collection and payment of premiums for life and LTD coverage; Web claims submission services; a suite of reporting tools; and direct deposit services. NexgenRx Inc. offers its benefits to plan sponsors, brokers, consultants, and third party administrators. The company was founded in 2003 and is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Health Care Plans
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-56.53%
Return on Assets-5.02%
NexgenRx (CVE:NXG) Frequently Asked Questions
What is NexgenRx's stock symbol?
NexgenRx trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NXG."
When will NexgenRx make its next earnings announcement?
Who are some of NexgenRx's key competitors?
Some companies that are related to NexgenRx include Uroplasty (UPI), WaferGen Bio-systems (WGBS), Aviragen Therapeutics (AVIR), Macrocure (MCUR), Can-Fite BioPharma (CANF), Scientific Digital Imaging (SDI), Midatech Pharma (MTPH), Surgical Innovations Group (SUN), Sonoma Pharmaceuticals (SNOA), DARA Biosciences (DARA), LiDCO Group (LID), Oxford Pharmascience Group (OXP), Check Cap (CHEK), Biopharmx (BPMX), Futura Medical (FUM), Synairgen (SNG), Venture Life Group (VLG) and Alliqua Biomedical (ALQA).
Who are NexgenRx's key executives?
NexgenRx's management team includes the folowing people:
- Thomas F. Corcoran, Chairman of the Board
- Ronald C. Loucks, President, Chief Executive Officer, Director
- Kelly Ehler CPA, Interim Chief Financial Officer
- Patrick G. Crowley, Director
- Barry J. Reiter, Director (Age 66)
- Ralph Soberano, Director
- David A. Rosenkrantz, Independent Director
How do I buy NexgenRx stock?
Shares of NexgenRx and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is NexgenRx's stock price today?
One share of NexgenRx stock can currently be purchased for approximately C$0.24.
How big of a company is NexgenRx?
NexgenRx has a market capitalization of C$14.42 million.
How can I contact NexgenRx?
NexgenRx's mailing address is 185 the West Mall Suite 600, ETOBICOKE, ON M9C 5L5, Canada. The company can be reached via phone at +1-416-6953393.
MarketBeat Community Rating for NexgenRx (NXG)MarketBeat's community ratings are surveys of what our community members think about NexgenRx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
NexgenRx (CVE:NXG) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for NexgenRx (CVE:NXG)
No earnings announcements for this company have been tracked by MarketBeat.com
NexgenRx (CVE:NXG) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for NexgenRx (CVE:NXG)
No dividend announcements for this company have been tracked by MarketBeat.com
NexgenRx (CVE NXG) Insider Trading and Institutional Ownership History
NexgenRx (CVE NXG) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/11/2017||Paul Everett Crossett||Insider||Buy||20,000||C$0.24||C$4,800.00|
|12/5/2017||Paul Everett Crossett||Insider||Buy||20,000||C$0.24||C$4,800.00|
|11/22/2017||Paul Everett Crossett||Insider||Buy||20,000||C$0.23||C$4,600.00|
|11/20/2017||Paul Everett Crossett||Insider||Buy||14,500||C$0.23||C$3,335.00|
|10/31/2017||Paul Everett Crossett||Insider||Buy||16,000||C$0.23||C$3,680.00|
|10/27/2017||Paul Everett Crossett||Insider||Buy||500||C$0.21||C$105.00|
|10/20/2017||Paul Everett Crossett||Insider||Buy||20,000||C$0.22||C$4,400.00|
|10/6/2017||Paul Everett Crossett||Insider||Buy||58,000||C$0.22||C$12,760.00|
|10/4/2017||Paul Everett Crossett||Insider||Buy||1,500||C$0.23||C$345.00|
|9/26/2017||Paul Everett Crossett||Insider||Buy||500||C$0.23||C$115.00|
|8/17/2017||Paul Everett Crossett||Insider||Buy||500||C$0.23||C$115.00|
|8/9/2017||Paul Everett Crossett||Insider||Buy||12,000||C$0.23||C$2,760.00|
|8/8/2017||Paul Everett Crossett||Insider||Buy||14,500||C$0.23||C$3,335.00|
|8/4/2017||Paul Everett Crossett||Insider||Buy||31,000||C$0.24||C$7,440.00|
|7/31/2017||Paul Everett Crossett||Insider||Buy||45,500||C$0.23||C$10,465.00|
|7/18/2017||Paul Everett Crossett||Insider||Buy||25,000||C$0.24||C$6,000.00|
|7/4/2017||Paul Everett Crossett||Insider||Buy||40,000||C$0.24||C$9,600.00|
|6/28/2017||Paul Everett Crossett||Insider||Buy||45,000||C$0.24||C$10,800.00|
|6/27/2017||Paul Everett Crossett||Insider||Buy||40,000||C$0.24||C$9,600.00|
|6/20/2017||Paul Everett Crossett||Insider||Buy||30,000||C$0.24||C$7,200.00|
|6/14/2017||Paul Everett Crossett||Insider||Buy||25,000||C$0.24||C$6,000.00|
|6/8/2017||Paul Everett Crossett||Insider||Buy||50,000||C$0.24||C$12,000.00|
|6/7/2017||Paul Everett Crossett||Insider||Buy||25,000||C$0.24||C$6,000.00|
|6/6/2017||Paul Everett Crossett||Insider||Buy||50,000||C$0.24||C$12,000.00|
|6/5/2017||Paul Everett Crossett||Insider||Buy||108,000||C$0.24||C$25,920.00|
|4/5/2017||Paul Everett Crossett||Insider||Buy||78,000||C$0.24||C$18,720.00|
|3/20/2017||Paul Everett Crossett||Insider||Buy||500||C$0.24||C$120.00|
|3/15/2017||Paul Everett Crossett||Insider||Buy||27,000||C$0.25||C$6,750.00|
|3/14/2017||Paul Everett Crossett||Insider||Buy||101,000||C$0.25||C$25,250.00|
|2/28/2017||Paul Everett Crossett||Insider||Buy||10,000||C$0.25||C$2,500.00|
|2/21/2017||Paul Everett Crossett||Insider||Buy||23,000||C$0.25||C$5,750.00|
|2/16/2017||Paul Everett Crossett||Insider||Buy||14,500||C$0.24||C$3,480.00|
|2/10/2017||Paul Everett Crossett||Insider||Buy||110,500||C$0.24||C$26,520.00|
|2/9/2017||Paul Everett Crossett||Insider||Buy||15,000||C$0.26||C$3,900.00|
|2/3/2017||Paul Everett Crossett||Insider||Buy||16,500||C$0.25||C$4,125.00|
|2/1/2017||Paul Everett Crossett||Insider||Buy||22,500||C$0.25||C$5,625.00|
|1/30/2017||Paul Everett Crossett||Insider||Buy||500||C$0.23||C$115.00|
|1/27/2017||Paul Everett Crossett||Insider||Buy||20,000||C$0.23||C$4,600.00|
|1/24/2017||Paul Everett Crossett||Insider||Buy||20,000||C$0.23||C$4,600.00|
|1/23/2017||Paul Everett Crossett||Insider||Buy||5,000||C$0.23||C$1,150.00|
|5/6/2016||Paul Everett Crossett||Insider||Buy||61,000||C$155.00||C$9,455,000.00|
|3/15/2016||Paul Everett Crossett||Insider||Buy||5,000||C$0.16||C$775.00|
|3/14/2016||Paul Everett Crossett||Insider||Buy||50,000||C$0.16||C$7,750.00|
|3/10/2016||Paul Everett Crossett||Insider||Buy||21,000||C$0.15||C$3,150.00|
|3/4/2016||Paul Everett Crossett||Insider||Buy||75,000||C$0.16||C$11,625.00|
|3/2/2016||Paul Everett Crossett||Insider||Buy||25,000||C$0.16||C$3,875.00|
|2/26/2016||Paul Everett Crossett||Insider||Buy||23,000||C$0.16||C$3,565.00|
|2/25/2016||Paul Everett Crossett||Insider||Buy||25,000||C$0.16||C$3,875.00|
|2/2/2016||Paul Everett Crossett||Insider||Buy||25,000||C$0.15||C$3,750.00|
|1/26/2016||Paul Everett Crossett||Insider||Buy||25,000||C$0.16||C$4,000.00|
|12/2/2015||Paul Everett Crossett||Insider||Buy||5,000||C$0.15||C$750.00|
|11/30/2015||Paul Everett Crossett||Insider||Buy||25,000||C$0.17||C$4,250.00|
|9/23/2015||Ronald Campbell Loucks||Director||Buy||100,000||C$0.15||C$15,000.00|
|6/30/2015||Ronald Campbell Loucks||Director||Buy||600,000||C$0.17||C$102,000.00|
NexgenRx (CVE NXG) News Headlines
No headlines for this company have been tracked by MarketBeat.com
NexgenRx (CVE:NXG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
NexgenRx (CVE NXG) Stock Chart for Tuesday, December, 12, 2017